The cytochrome P450 2D6 (CYP2D6) isoenzyme metabolizes about 25% of clinically used drugs. The impact of CYP2D6 metabolizer status on therapeutic outcome was assessed in 365 psychiatric in-patients treated with neuroleptics or antidepressants. Length of hospitalization and response onset were prolonged for patients receiving CYP2D6 drugs. Intermediate metabolizers (IMs) receiving CYP2D6 doses above the population median had more side effects after 4 weeks than extensive metabolizers with abovemedian doses (9/13, 69% vs 4/23, 17%, P ¼ 0.003), than IMs with belowmedian doses (5/22, 23%, P ¼ 0.012) and IMs with other medication (24/84, 29%, P ¼ 0.009). The Clinical Global Impression scale response was lower for IMs treated with CYP2D6 drugs (3/42, 7%) than for IMs with other medication (21/84, 25%, P ¼ 0.017) probably due to increased side effects. Identification of IM status (38% of study population) may help to reduce side effects and length/cost of hospitalization. Thus, not only poor and ultrarapid metabolizer but also IMs may benefit from CYP2D6 genotyping. This is of paramount interest since it greatly improves cost/benefit estimations for pretreatment CYP2D6 screening.
Introduction
Many clinically used drugs, especially lipophilic compounds, are metabolized before excretion in urine or bile. Cytochrome P450 enzymes are responsible for 70-80% of all phase-I-dependent metabolism in approximately 40-45% of all marketed drugs. 1 Genetic polymorphisms have been shown to cause wide interindividual differences in the metabolic activity of CYP P450 enzymes, thus influencing pharmacokinetics, efficacy and adverse effects of pharmaceutical drug treatment. 2 Especially well characterized is the highly polymorphic cytochrome P450 2D6 (CYP2D6) isoenzyme for which over 80 alleles and over 150 variations have been described with widely varying frequencies between different ethnicities (cf Home Page of the Human Cytochrome P450 Allele Nomenclature Committee, http:// www.imm.ki.se/cypalleles). Variable expression and function of the CYP2D6 alleles leads to abolished, reduced or increased enzyme activity. This forms four distinct phenotypes: poor metabolizers (PMs) lacking functional enzyme, intermediate metabolizers (IMs) with residual activity due to the presence of at least one completely or two partially deficient alleles, extensive metabolizers (EMs) carrying two functional gene copies and ultrarapid metabolizers (UMs) carrying more than two functional gene copies. 3 In central Europe, 2-5% of the population are UMs and 5-10% PMs. Owing to the inclusion of the new CYP2D6*41 allele, recent estimations for IMs reach up to approximately 30-40% of the population. 4, 5 This enzyme is involved in the metabolism of approximately 25% of the clinically used drugs. The dosing required to achieve the same plasma levels of a drug mainly metabolized by CYP2D6 can differ 10-to 30-fold between individuals. 1 Thus, standard doses of drugs in PMs can either lead to exaggerated drug response or excessive side effects whereas the other extreme, that is UMs, may suffer from therapeutic failure as they show extremely high enzymatic activity resulting in lower drug concentrations. The function of the CYP2D6 polymorphisms in drug interaction profiles, side effects and therapeutic outcome is well documented for UMs and PMs. [6] [7] [8] [9] [10] Genotyping before treatment has been postulated as a useful tool in preventing side effects and providing dose recommendations. 11, 12 However, there are little data on the clinical impact of CYP2D6 polymorphisms on therapeutic drug treatment, response to therapy and side effects of IMs.
Some of the drugs most markedly affected are used in psychiatry, for example, almost all tricyclic antidepressants, some newer selective serotonin reuptake inhibitors and many antipsychotic drugs. The goal of this study was, therefore, to assess the potential impact of the CYP2D6 genotype on pharmacotherapy, therapeutic outcome and side effects in psychiatric in-patients.
Results

Baseline characteristics
In total, 489 patients eligible for inclusion in the study gave informed consent and were initially included in the study. No DNA sample was available for 58 patients. Hospitalization of 65 patients was too short to provide enough data for further statistical evaluation. Thus, genotyping and statistical analysis were performed for 365 patients of which 8.5% (31) were CYP2D6 PMs, 37.8% (138) IMs, 50.6% (185) EMs and 3.0% (11) UMs.
Baseline demographics are given in Table 1 . Of the 365 patients, 162 (44%) were men. Mean±standard deviation age was 44 ± 16 years. The ICD-10 diagnosis assigned by the treating psychiatrists included mood disorders (F3, n ¼ 164), schizophrenia and other psychotic disorders (F2, n ¼ 174) and other diagnoses (F4-neurotic, stress-related and somatoform disorders and F6-disorders of adult personality and behavior, n ¼ 27).
The different CYP2D6 groups were compared regarding baseline demographics, diagnosis and anamnestic data (number of previous episodes, duration of previous hospital stays as far as available). No significant differences were observed. UMs showed a trend to a higher rate of switches due to nonresponse in medical history (3/11, 27% compared to 35/293, 12% for all others, data for n ¼ 304 available, odds ratio 2.8, P ¼ 0.15).
Regarding the whole study population, 108 (30%) patients received at least one of the following CYP2D6 substrates: amitriptyline (7 Â ), clomipramine (1 Â ), imipramine (1 Â ), doxepin (17 Â ), trimipramine (16 Â ), fluoxetine (10 Â ), paroxetine (16 Â ), aripiprazole (3 Â ), chlorpromazine (11 Â ), promethazin (8 Â ), haloperidol (25 Â ) and zuclopenthixol (5 Â ). Only drugs where the enzyme is significantly involved in the metabolism were included. The classification was carried out according to the published literature. 11, 13, 14 Complete data on exact dosage within the first 4 weeks were available for 353 of the 365 patients. We calculated the relative doses per CYP2D6 substrate per patient based on the daily dose as defined by the WHO for each drug. 15 The relative doses were summarized for each patient. The mean doses applied during the first 4 weeks-in relation to the defined daily doses-are given in Table 1 for the different CYP2D6 metabolizer groups. UMs and PMs tended to receive slightly lower doses of CYP2D6-dependent drugs than EMs and IMs. The observed differences were not significant (P40.5).
CYP2D6 gene dose and prescription frequencies of CYP2D6 substrates As shown by Figure 1 , only 4 of the 31 PMs (13%) were treated with CYP2D6 substrates, but 4 of 11 UMs (36%) were treated with CYP2D6 related drugs. Interestingly, like in PMs, the prescription frequency of the patients with severely impaired metabolism (gene dose 0.5) was lower than the population mean (4 out of 20, 20%). For the gene doses 1, 1.5 and 2, similar and higher prescription frequencies were observed (35, 32 and 29%, respectively), which approximate the overall mean of 30%. The difference between gene doses 0 and 0.5 on the one hand and gene dose X1 was significant (P ¼ 0.020; odds ratio 2.5).
CYP2D6 gene dose and course of illness
In our study population, length of hospitalization and response onset were prolonged for patients treated with CYP2D6-dependent drugs. On average, patients with CYP2D6-dependent medication were hospitalized 6 days longer (63 ± 37 days, n ¼ 108) than those treated with other drugs (57±38 days, n ¼ 257; Mann-Whitney U-test, P ¼ 0.075) and they responded 4 days later to pharmacotherapy (n ¼ 88, 34 ± 27 days vs n ¼ 235, 30 ± 30 days, P ¼ 0.034, data of 323 patients available). Of the 42 patients who did not respond to pharmacotherapy during their hospital stay, 20 were treated with CYP2D6-dependent drugs.
Comparison of PMs, IMs, EMs and UMs did not show any significant differences in the length of hospitalization (52, 64, 63 and 63 days for 4 PMs, 45 IMs, 55 EMs and 4 UMs, respectively, P40.8). Also, the response onset was similar (28, 34, 35 and 34 days for 4 PMs, 33 IMs, 48 EMs and 3 UMs, respectively, P40.6). In the patient group receiving CYP2D6 drugs, a pronounced, significant increase of side effects was observed for the PMs. They had significantly higher adverse drug effects (DOTES) sum scores (on average 7.7 score points) than nonPMs (on average 2.0 score points, P ¼ 0.007; Table 2 ). As shown in Figure 2 , all PMs receiving CYP2D6 substrates (3/3) had marked or moderate side effects according to the overall rating by the treating psychiatrist, whereas only 39% of the IMs (15/38), 22% of the EMs (11/50) and 25% of the UMs (1/ 4) suffered from at least moderate side effects (see Table 2 , P ¼ 0.029 for PMs vs non-PMs). The side effects were not elevated if the PMs received non-CYP2D6-dependent medication (PMs 9/25, 36% vs IMs 24/84, 29%; EMs 31/117, 26% and UMs 1/7, 14%, P ¼ 0.351). Correspondingly, the DOTES sum scores were similar between PMs (on average 2.8 score points) and all others receiving non-CYP2D6-dependent medication (on average 2.3 score points).
The difference in adverse effects in PMs with and without CYP2D6-dependent medication failed to reach significance due to the low number of patients (3/3, 100% vs 9/25, 36%, P ¼ 0.067).
IMs vs EMs.
Intermediate metabolizers treated with CYP2D6 medication suffered from more moderate/marked side effects than EMs (39 vs 22%, P ¼ 0.099; see Table 2 ), however, this was not statistically significant. Similar results were observed when only patients with exact dosing data were evaluated (n ¼ 91). The incidence of side effects tended to be higher in IMs than in EMs receiving CYP2D6 medication (14/35, 40% vs 10/49, 20%, Fisher's exact test, P ¼ 0.085).
As shown in Figure 3 , both groups were further subdivided into those receiving daily doses of CYP2D6 substrates above the population median and those below or equal. A statistically significant difference was observed between IMs and EMs receiving doses above the population median (IMs 9/13, 69% and EMs 4/23, 17%, Fisher's exact test, P ¼ 0.003), but not for those whose doses were below or equal the population median (IMs 5/22, 23% and EMs 6/26, 23%, P ¼ 1.0). PMs and UMs were not further subdivided because of the small sample size.
Intermediate metabolizers treated with daily doses of CYP2D6 substrates above the population median had also more side effects than IMs receiving doses below or equal to the population median (9/13, 69% vs 5/22, 23%, P ¼ 0.012, odds ratio 7.7; Figure 3 ) or IMs without CYP2D6-dependent medication (69% vs 24/84, 29%, P ¼ 0.009, odds ratio 5.6). No such differences were observed for EMs receiving doses above vs those receiving below or equal to the median (4/23, 17% vs 6/26, 23%, P ¼ 0.731; see Figure 3 ) or vs those Table 2 , the overall CGI(2) responder rate to CYP2D6-dependent medication and non-CYP2D6-dependent medication was comparable with 14% (14/99) and 18% (42/239, P ¼ 0.5). No significant difference was observed for the EM subgroup as well (9/49, 18% vs 13/125, 10%, P ¼ 0.203). As shown in Figure 4 , only 7% (3/42) of IMs receiving CYP2D6-dependent medication, but 25% (21/84) of patients without CYP2D6 drugs responded (P ¼ 0.017).
Within the patients receiving CYP2D6-dependent medication, the difference in the responder rate was not significant for IMs vs EMs (3/42, 7% vs 9/49, 18%, Fisher's exact test, P ¼ 0.134). Surprisingly, the difference was significant for non-CYP2D6-dependent medication (21/84, 25% vs 13/125, 10%, P ¼ 0.007; see Figure 4 ).
Comparison of CYP2D6 drug doses (above vs below or equal to the median) showed no significant differences in responder rates (IMs below median 2/25, 8% and above the median 1/14, 7%; P ¼ 1.0; EMs below median 4/27, 15% and above the median 5/21, 24%, P ¼ 0.477). Interestingly, treatment response increased continuously with the gene dose for above-median doses (gene dose 0: 0/2, 0%; gene dose 0.5: 0/2, 0%; gene dose 1: 1/12, 8%; gene dose 1.5: 1/5, 20%; gene dose 2: 4/16, 25% and gene dose >2: 1/1, 100% Pearson's w 2 -test, P ¼ 0.091). This was, however, not significant probably due to the low number of patients per 
Discussion
CYP2D6 gene dose and prescription frequencies of CYP2D6 substrates CYP2D6 metabolizes about 25% of clinically used drugs and many psychoactive substances require CYP2D6 for metabolism. In our study population, 108 (30%) of the patients received psychotropic drugs that are predominantly metabolized by CYP2D6 (see Figure 1) . The significantly lower prescription frequencies for the patients with poor or severely impaired CYP2D6 metabolism (CYP2D6 gene doses 0 or 0.5, 13 and 20%) may reflect unfavorable effects under CYP2D6-dependent medication and subsequent switch in medical history. All patients with gene dose 0 or 0.5 had been treated for more than 1 year before being hospitalized during the current study.
CYP2D6 gene dose and course of illness
Hospitalization of patients with CYP2D6-dependent medication tended to be longer (on average 6 days, P ¼ 0.075) and they responded significantly later (on average 4 days, P ¼ 0.034) than patients on other drugs. This is in line with previous findings 7 but has to be carefully interpreted due to the limited number of patients in the study. A possible explanation could be that the metabolic pathway mediated by CYP2D6 is easily inhibited or saturated by a multitude of psychoactive or cardiovascular co-medication. 16 The resulting drug-drug interactions may delay response to drug treatment.
Comparison of PMs, IMs, EMs and UMs did not show any significant differences in the length of hospitalization or response onset. A prolonged hospital stay may either be due to unsatisfactory treatment response (expected especially for UMs) or side effects (PMs). In clinical practice, these cases cannot be assigned easily without therapeutic drug monitoring and/or pharmacogenetic testing. Side effects may mimic the psychiatric illness and therapeutic failure due to ultrarapid metabolism may be mistaken for poor compliance with the prescription. 17 The doses of CYP2D6-dependent drugs were similar for all genotype groups (P40.5; see Table 1 ). UMs did not receive higher doses as suggested previously. 11, 12 The treating psychiatrists, however, were unaware of the genotypes and thus dose titration matching the patients' metabolic capacity could not be expected. and extensive metabolizers (EMs) in relation to dose. IMs with high doses (i.e., above the population median) had more side effects than EMs receiving high doses (P ¼ 0.003) and IMs receiving low doses (i.e., below/equal the median, P ¼ 0.012). No significant differences were observed for IMs and EMs receiving low doses (P ¼ 1.0) or between EMs receiving high or low doses (P ¼ 0.731). Note: the administered dose was calculated as a fraction of the WHO-defined daily dose for each CYP2D6 drug substrate and in case of more than one CYP2D6 drug per patient summarized for a 4-week period. Dosing and side effect data were available for 91 patients (3 poor metabolizers, PMs; 35 IMs; 49 EMs and 4 ultrarapid metabolizers, UMs).
CYP2D6 gene dose and adverse drug effects
A pronounced, significant increase of side effects was observed for PMs compared to non-PMs (P ¼ 0.029; see Figure 2 ) when receiving CYP2D6 drugs but not for other drugs. The difference in adverse effects in PMs with and without CYP2D6-dependent medication just failed to reach statistical significance, probably due to the low number of patients (3/3, 100% vs 9/25, 36%, P ¼ 0.067; see Table 2 ). It is, however, in line with previous findings. [6] [7] [8] [9] [18] [19] [20] Intermediate metabolizers treated with CYP2D6 medication suffered from somewhat more moderate/marked side effects than EMs (39 vs 22%, P ¼ 0.099; see Figure 2 ). When both groups were further subdivided into those receiving daily doses of CYP2D6 substrates above the population median and those below or equal, IMs treated with higher CYP2D6 doses displayed more side effects than EMs (9/13, 69% vs 4/23, 17%, P ¼ 0.003; see Figure 3 ). They also had more side effects than IMs receiving below-median doses (5/ 22, 23%, P ¼ 0.012) and IMs with other medication (24/84, 29%, P ¼ 0.009). IMs and EMs with below-median doses had comparable adverse effect rates (both 23%, P ¼ 1.0).
The impact of the CYP2D6 polymorphism on plasma or serum concentrations of CYP2D6-dependent drugs has been examined in several studies. Based on the results, dose adjustment has been suggested for PMs, IMs and UMs. 11, 12 A number of studies on PMs suffering from more side effects have been published, but reports on the impact of IMs on clinical outcome are rare and mostly concentrate on pharmacokinetics. 21, 22 The genetic basis of the most frequent polymorphism with impaired function in Caucasians, CYP2D6*41, has only been discovered in the past few years 5, 23, 24 and was not included in most former studies leading to inaccuracies in gene dose assignment. Recently, 40% of the Caucasian population have been estimated as having IM status.
Thus, not only the relatively small number of PMs (5-10% in central Europe) and UMs (2-5%) but also IMs and EMs may benefit from CYP2D6 genotyping. Identification of IM status might help to avoid adverse effects by starting treatment with lower doses for CYP2D6 drugs and keeping doses low throughout the treatment. In the case of nonresponse, switching to another drug might be better than increasing the dose for IMs. Increasing the dose, however, would be an option for EMs and UMs.
CYP2D6 gene dose, administered dose and treatment response
Intuitively one might expect increased response from treatment with CYP2D6 drugs in IMs (and PMs) as they reach higher concentrations per dose than EMs (and UMs). This does not seem to be the case. IMs showed even less response under CYP2D6 treatment than EMs (3/42, 7% vs 9/ 49, 18%, Fisher's exact test, P ¼ 0.134; see Figure 4 ). The sample sizes of the PMs and UMs in our population were too small for a meaningful conclusion. Accordingly, no significant differences in response rates were found for the different CYP2D6 metabolizer groups in previous studies. 25, 26 CYP2D6-medicated IMs showed also less response than IMs treated with other drugs after 4 weeks of treatment (3/ 42, 7% vs 21/84, 25%, P ¼ 0.017). The lower response may be due to the higher adverse effects frequency of IMs under CYP2D6 medication. Suffering from unpleasant side effects may lead to underrating of the improvement. No such effect was observed for the EMs. The EM (and the overall) responder rate was comparable between CYP2D6 drugs and other drugs (EM 18 vs 10%, P40.2; overall 14/99, 14% and 42/239, 18%, P40.5; see Table 2 ).
Responder rates under CYP2D6 treatment were similar for the IMs treated with doses below or above the study population median (IMs 2/25, 8% vs 1/14, 7%, P ¼ 1.0). Similarly, no correlation between drug concentrations or genotypes and therapeutic response of amitriptyline-treated patients was found previously, though a correlation with side effects was observed. 26 This implies that dose reduction due to side effects as proposed for IMs does not interfere with the efficacy of treatment.
Yet treatment response seemed to increase continuously with gene dose for doses above the population median (gene dose 0: 0/2, 0%, gene dose 0. . Surprisingly, the difference of IMs vs EMs was significant for non-CYP2D6-dependent medication (P ¼ 0.007).
CYP2D6 IMs and side effects
B Laika et al group, however, does not allow any statistically sound conclusion. It appears that lower doses may be a limiting factor for treatment response in higher gene dose groups. Some of the evaluated CYP2D6 drugs (such as the tricyclic antidepressants) have narrow therapeutic windows and relatively cautious dose recommendations to prevent side effects at higher doses. Accordingly, increased doses for EMs and/or UMs have been proposed earlier for some CYP2D6 substrates. 11, 12 This conforms to our observations. Thus, genotyping might help to forecast an appropriate initial dose in any given patient; not only to prevent side effects in PMs and IMs but also to ensure exposure and response in both EMs and UMs.
Unexpectedly responder rates were higher for IMs than EMs when patients received non-CYP2D6 drugs (21/84, 25% vs 13/125, 10%, P ¼ 0.007; see Table 2 ). IMs are more prone to adverse effects under CYP2D6 substrates, which may mimic the illness itself or may have led to noncompliance in the past. These incompatibilities known from medical history may have led to drug switch at the very beginning of the current hospital stay and subsequent treatment success that was not achieved with CYP2D6 drugs used before. This is also supported by the fact that the prescription frequency of CYP2D6-dependent drugs in the present treatment was lower than the overall mean for IMs (especially with gene dose 0.5).
Overall summary and conclusion
Patients treated with CYP2D6 drugs suffered from prolonged hospitalization (NS) and delayed response onset (4 days). Pretreatment genotyping and dose adjustment may help to avoid side effects and lead to better response resulting in shorter hospitalization.
Despite studying 365 patients, especially the number of PMs (8.5%) and UMs (3%) was too small for statistically sound conclusions. Trends for UMs (more switches due to nonresponse in medical history) and EMs (continuous increase of responder rate with gene dose only in the case of above-median CYP2D6 drug doses) suggest that the recommended standard doses may be insufficient for optimal treatment response in these groups.
Comparison of IMs (gene dose 0.5 or 1) and EMs (gene dose 1.5 or 2) showed that:
IMs treated with higher doses of CYP2D6-dependent drugs suffered from significantly more side effects than * IMs treated with lower doses of CYP2D6 drugs, * EMs treated with higher doses of CYP2D6 drugs and * IMs treated with other medication. Treatment response was lower under CYP2D6 medication than under non-CYP2D6 medication for IMs, but not for EMs. This may be a consequence of more side effects under CYP2D6 medication. IMs treated with high or low doses of CYP2D6 drugs had comparable response rates. Lower doses do not seem to limit treatment response in IMs.
Our results imply that genotyping may be beneficial not only to PMs (side effects) and UMs (lack of response) but also IMs and EMs. Whereas EMs are more likely to accept higher doses of therapeutic agents, IMs are inclined to suffer from adverse events when treated with above average doses of CYP2D6 drugs. Therefore, lack of response in EMs (and UMs) could be dealt with by dose escalation whereas a compound switch is more promising in IMs (and PMs) to obviate bothering drug side effects.
In this scenario not only 6-10% of PMs and 2-5% of UMs potentially benefit from genotyping but every patient on CYP2D6 drugs. This challenges any past benefit/cost estimations and sheds a brand new light on the medical and financial benefits of screening by pretreatment genotyping.
Our conclusions drawn from a relatively small set of patients, however, should be regarded with caution. The associations found should be replicated in larger, more controlled settings. Additional monitoring of drug concentrations as the link between CYP2D6 metabolic status and clinical response as exemplified in a previous study on amitriptyline 26 would be useful.
Materials and methods
Study design
Patients were recruited between 2002 and 2005 at the psychiatric department at Klinikum rechts der Isar, Munich, Germany. This study was approved by the local ethics committee and was carried out in accordance with the principles of the Declaration of Helsinki. Patients were informed of the aims of the study and gave written consent, which could be withdrawn at any time. The patients were treated according to local clinical practice with regard to the relevant guidelines. The treating physician and the patients were masked to genotype. The design of the study was open and drug dosage could be adjusted individually as clinically indicated. Inclusion criteria were schizophrenia and other psychotic conditions (ICD-10: F2), mood disorders (ICD-10: F3) and other disorders necessitating treatment with neuroleptics or antidepressants. Patients younger than 18 years, patients suffering from organic disorders (ICD-10: F0) or drug addicts (ICD-10: F1) were excluded from the study. Further exclusion criteria were breast-feeding or pregnancy. No patients admitted to hospital by law or authority direction were included in the study.
Patient data including demographic data, diagnosis according to ICD-10, medical anamnesis and case history, drug treatment and length of hospitalization were determined in a structured interview and collected from medical charts. Changes in drug therapy as well as concomitant medication were recorded during the first 4 weeks.
The treating psychiatrist assessed the course of illness for each patient on admission, after 4 weeks and before dismissal using the CGI scale 27 including the CGI(1) severity and CGI(2) improvement rating and gave a statement regarding onset of response to the treatment. Moreover, adverse drug events were evaluated after 4 weeks of therapy according to a varied version of the DOTES score 27 including an overall rating (none, mild, moderate, marked). Side effects were evaluated as 'positive' for overall side effect ratings of moderate/marked and if probably caused by the psychotropic drugs.
Genotyping CYP2D6 genotyping was carried out as described elsewhere [28] [29] [30] for detection of the gene duplication and deletion (CYP2D6*5), for the functional alleles *1 and *2 (formerly *2G); for the dysfunctional alleles *3, *4, *6, *7 and *8; for the alleles with reduced function *9, *10, *41 and for the differentiation of gene duplication as *1 Â N, *2 Â N and *4 Â N. 31 The *41 (formerly *2C) was characterized with a fluorescence-based LightCycler hybridization probes assay by the novel polymorphism 2988G4A within intron 6, which was in almost complete linkage to the former À1584C4G change. The following CYP2D6 allele frequencies-similar to published data 4,5 -were found: *1 (39.0%), *2 (18.1%), *3 (2.6%), *4 (21%), *5 (2.9%), *6 (1.1%), *9 (2.2%), *10 (2.2%), *41 (8.2%), *1 Â N (1.6%), *2 Â N (1.0%) and *4 Â N (0.1%).
To allow an evaluation of the highly polymorphic CYP2D6 gene, we rated the different polymorphisms according to their functionality with semiquantitative gene doses as described by Steimer et al. 32 The nonfunctional alleles were rated with gene dose 0, the impaired alleles with gene dose 0.5, the functional alleles *1 and *2 with gene dose 1, and for duplicated genes the respective gene dose was doubled. In a second step, the gene dose of 0 was rated as PM, 0.5 and 1 as IM, 1.5 and 2 as EM and 42 as UM to obtain sufficiently large groups for statistical evaluation.
Statistics
The different CYP2D6 gene doses as well as metabolizer groups were compared with regard to baseline demographics, diagnostic and anamnestic data (number of previous episodes, duration of previous hospital stays and length of current stay, all available data).
Statistical analysis was performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Two-tailed P-values o0.05 were considered to be of statistical significance. Fisher's exact test and w
